/PRNewswire/ Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that Cuthbert Simpkins.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic.
Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Adrenomed, MYND Life Sciences, Inotrem, Vivacelle Bio,
Palisade Bio, Baxter Healthcare Corporation, RegeneRx Biopharmaceuticals, Pharmazz, Inc., La Jolla Pharmaceutical, and others are developing potential drug candidates to improve the Septic Shock treatment scenario.
Key Septic shock pipeline candidates such as
Adrecizumab,
Nangibotide,
Tranexamic acid, Timbetasin, VBI-S, OctaplasLG, and others are under investigation in different phases of clinical trials to treat Septic shock.
Adrecizumab is a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is bolstered by the elegance of its mode of action. This monoclonal antibody on binding to its target Adrenomedullin preserves its functionality as a regulator of vascular integrity. Adrecizumab is currently under clinical evaluation. In the AdrenOSS-2, proof-of-concept phase II trial in septic shock, Adrecizumab shown a favorable safety profile, was well tolerated and